List of Tables
Summary Table: Global Market for Antibody Drugs, by Region, Through 2029
Table 1: Evolution of Monoclonal Antibodies, 1908-2024
Table 2: Advantages and Disadvantages of Monoclonal Antibodies
Table 3: Differences between Hybridoma and Recombinant Technologies
Table 4: Incidence and Mortality Rates of Cancer Across Regions, 2022
Table 5: Therapeutic Area Distribution of Approved Antibody Drugs, 2023*
Table 6: Approved Antibody Products for Rare Autoimmune Diseases
Table 7: Listed Pricing of Select Antibody Drugs in the U.S.
Table 8: Newly Approved Monoclonal Antibodies, 2022-July 2024
Table 9: Top Selling Antibody Drugs, 2023
Table 10: Global Market for Antibody Drugs, by Antibody Type, Through 2029
Table 11: Global Market for Human Monoclonal Antibodies, by Region, Through 2029
Table 12: North American Market for Human Monoclonal Antibodies, by Country, Through 2029
Table 13: European Market for Human Monoclonal Antibodies, by Country, Through 2029
Table 14: Asia-Pacific Market for Human Monoclonal Antibodies, by Country, Through 2029
Table 15: Global Market for Humanized Monoclonal Antibodies, by Region, Through 2029
Table 16: North American Market for Humanized Monoclonal Antibodies, by Country, Through 2029
Table 17: European Market for Humanized Monoclonal Antibodies, by Country, Through 2029
Table 18: Asia-Pacific Market for Humanized Monoclonal Antibodies, by Country, Through 2029
Table 19: Global Market for Chimeric Monoclonal Antibodies, by Region, Through 2029
Table 20: North American Market for Chimeric Monoclonal Antibodies, by Country, Through 2029
Table 21: European Market for Chimeric Monoclonal Antibodies, by Country, Through 2029
Table 22: Asia-Pacific Market for Chimeric Monoclonal Antibodies, by Country, Through 2029
Table 23: Global Market for Murine Monoclonal Antibodies, by Region, Through 2029
Table 24: North American Market for Murine Monoclonal Antibodies, by Country, Through 2029
Table 25: European Market for Murine Monoclonal Antibodies, by Country, Through 2029
Table 26: Asia-Pacific Market for Murine Monoclonal Antibodies, by Country, Through 2029
Table 27: Global Market for Antibody Drugs, by Manufacturing Process, Through 2029
Table 28: Global Market for Antibody Drugs Produced by Mammalian Cell Culture, by Region, Through 2029
Table 29: North American Market for Antibody Drugs Produced by Mammalian Cell Culture, by Country, Through 2029
Table 30: European Market for Antibody Drugs Produced by Mammalian Cell Culture, by Country, Through 2029
Table 31: Asia-Pacific Market for Antibody Drugs Produced by Mammalian Cell Culture, by Country, Through 2029
Table 32: Global Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Region, Through 2029
Table 33: North American Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Country, Through 2029
Table 34: European Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Country, Through 2029
Table 35: Asia-Pacific Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Country, Through 2029
Table 36: Global Market for Antibody Drugs, by Application, Through 2029
Table 37: Types of Autoimmune Diseases
Table 38: Global Antibody Drugs Market for Autoimmune Diseases, by Region, Through 2029
Table 39: North American Market for Antibody Drugs for Autoimmune Diseases, by Country, Through 2029
Table 40: European Market for Antibody Drugs for Autoimmune Diseases, by Country, Through 2029
Table 41: Asia-Pacific Market for Antibody Drugs for Autoimmune Diseases, by Country, Through 2029
Table 42: Global Market for Antibody Drugs for Solid Tumors, by Region, Through 2029
Table 43: North American Market for Antibody Drugs for Solid Tumors,, by Country, Through 2029
Table 44: European Market for Antibody Drugs for Solid Tumors, by Country, Through 2029
Table 45: Asia-Pacific Market for Antibody Drugs for Solid Tumors, by Country, Through 2029
Table 46: Types of Leukemia
Table 47: Global Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Region, Through 2029
Table 48: North American Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Country, Through 2029
Table 49: European Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Country, Through 2029
Table 50: Asia-Pacific Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Country, Through 2029
Table 51: Global Market for Antibody Drugs for Other Diseases, by Region, Through 2029
Table 52: North American Market for Antibody Drugs for Other Diseases, by Country, Through 2029
Table 53: European Market for Antibody Drugs for Other Diseases, by Country, Through 2029
Table 54: Asia-Pacific Market for Antibody Drugs for Other Diseases, by Country, Through 2029
Table 55: Global Market for Antibody Drugs, by Region, Through 2029
Table 56: North American Market for Antibody Drugs, by Country, Through 2029
Table 57: North American Market for Antibody Drugs, by Antibody Type, Through 2029
Table 58: North American Market for Antibody Drugs, by Manufacturing Process, Through 2029
Table 59: North American Market for Antibody Drugs, by Application, Through 2029
Table 60: European Market for Antibody Drugs, by Country, Through 2029
Table 61: European Market for Antibody Drugs, by Antibody Type, Through 2029
Table 62: European Market for Antibody Drugs, by Manufacturing Process, Through 2029
Table 63: European Market for Antibody Drugs, by Application, Through 2029
Table 64: Asia-Pacific Market for Antibody Drugs, by Country, Through 2029
Table 65: Asia-Pacific Market for Antibody Drugs, by Antibody Type, Through 2029
Table 66: Asia-Pacific Market for Antibody Drugs, by Manufacturing Process, Through 2029
Table 67: Asia-Pacific Market for Antibody Drugs, by Application, Through 2029
Table 68: RoW Market for Antibody Drugs, by Antibody Type, Through 2029
Table 69: RoW Market for Antibody Drugs, by Manufacturing Process, Through 2029
Table 70: RoW Market for Antibody Drugs, by Application, Through 2029
Table 71: Top Antibody Drug Companies, by Sales, 2023
Table 72: Major Acquisitions and Alliances in the Antibody Drugs Industry, 2022-2024
Table 73: Monoclonal Antibodies in Phase I Clinical TrialsMonoclonal Antibodies in Phase I Clinical Trials
Table 74: Monoclonal Antibodies in Phase II Clinical Trials
Table 75: Monoclonal Antibodies in Phase III Clinical Trials
Table 76: Monoclonal Antibodies in Phase IV Clinical Trials
Table 77: ESG Rankings for Major Antibody Drug Companies, 2024*
Table 78: ESG: Environmental Overview
Table 79: ESG: Social Factors Overview
Table 80: ESG: Governance Overview
Table 81: Report Sources
Table 82: Glossary of Terms Used in the Antibody Drugs Market
Table 83: AbbVie Inc.: Company Snapshot
Table 84: AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 85: AbbVie Inc.: Product Portfolio
Table 86: AbbVie Inc.: News/Key Developments, 2022-2024
Table 87: Amgen Inc.: Company Snapshot
Table 88: Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 89: Amgen Inc.: Product Portfolio
Table 90: Amgen Inc.: News/Key Developments, 2022-2023
Table 91: AstraZeneca: Company Snapshot
Table 92: AstraZeneca: Financial Performance, FY 2022 and 2023
Table 93: AstraZeneca: Product Portfolio
Table 94: AstraZeneca: News/Recent Developments, 2021-2024
Table 95: Bristol-Myers Squibb Co.: Company Snapshot
Table 96: Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 97: Bristol-Myers Squibb Co.: Product Portfolio
Table 98: Bristol-Myers Squibb Co.: News/Key Developments, 2022-2023
Table 99: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 100: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 101: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 102: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023-2024
Table 103: Johnson & Johnson Services Inc.: Company Snapshot
Table 104: Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 105: Johnson & Johnson Services Inc.: Product Portfolio
Table 106: Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
Table 107: Lilly: Company Snapshot
Table 108: Lilly: Financial Performance, FY 2022 and 2023
Table 109: Lilly: Product Portfolio
Table 110: Lilly: News/Key Developments, 2023-2024
Table 111: Merck KGaA: Company Snapshot
Table 112: Merck KGaA: Financial Performance, FY 2022 and 2023
Table 113: Merck KGaA: Product Portfolio
Table 114: Merck KGaA: News/Key Developments, 2022-2024
Table 115: Novartis AG: Company Snapshot
Table 116: Novartis AG: Financial Performance, FY 2022 and 2023
Table 117: Novartis AG: Product Portfolio
Table 118: Novartis AG: News/Key Developments, 2022-2024
Table 119: Pfizer Inc.: Company Snapshot
Table 120: Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 121: Pfizer Inc.: Product Portfolio
Table 122: Pfizer Inc.: News/Key Developments, 2023
Table 123: Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 124: Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 125: Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 126: Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2023
Table 127: Sanofi: Company Snapshot
Table 128: Sanofi: Financial Performance, FY 2022 and 2023
Table 129: Sanofi: Product Portfolio
Table 130: Sanofi: News/Key Developments, 2022-2023
List of Figures
Summary Figure: Global Market Share of Antibody Drugs, by Region, 2023
Figure 1: Dynamics of the Global Market for Antibody Drugs
Figure 2: Emerging Technologies in the Antibody Drugs Market
Figure 3: Global Market Share of Antibody Drugs, by Antibody Type, 2023
Figure 4: Global Market for Human Monoclonal Antibodies, by Region, 2021-2029
Figure 5: Global Market for Humanized Monoclonal Antibodies, by Region, 2021-2029
Figure 6: Global Market for Chimeric Monoclonal Antibodies, by Region, 2021-2029
Figure 7: Global Market for Murine Monoclonal Antibodies, by Region, 2021-2029
Figure 8: Global Market Share of Antibody Drugs, by Manufacturing Process, 2023
Figure 9: Global Market for Antibody Drugs Produced by Mammalian Cell Culture, by Region, 2021-2029
Figure 10: Global Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Region, 2021-2029
Figure 11: Global Market Share of Antibody Drugs, by Application, 2023
Figure 12: Global Antibody Drugs Market for Autoimmune Diseases, by Region, 2021-2029
Figure 13: Global Market for Antibody Drugs for Solid Tumors, by Region, 2021-2029
Figure 14: Global Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Region, 2021-2029
Figure 15: Global Market for Antibody Drugs for Other Diseases, by Region, 2021-2029
Figure 16: Global Market Share of Antibody Drugs, by Region, 2023
Figure 17: Global Market for Antibody Drugs, by Region, 2021-2029
Figure 18: North American Market Share of Antibody Drugs, by Country, 2023
Figure 19: U.S. Market for Antibody Drugs, 2021-2029
Figure 20: Canadian Market for Antibody Drugs, 2021-2029
Figure 21: Mexican Market for Antibody Drugs, 2021-2029
Figure 22: European Market Share of Antibody Drugs, by Country, 2023
Figure 23: German Market for Antibody Drugs, 2021-2029
Figure 24: French Market for Antibody Drugs, 2021-2029
Figure 25: Italian Market for Antibody Drugs, 2021-2029
Figure 26: Spanish Market for Antibody Drugs, 2021-2029
Figure 27: U.K. Market for Antibody Drugs, 2021-2029
Figure 28: Rest of Europe Market for Antibody Drugs, 2021-2029
Figure 29: Asia-Pacific Market Share of Antibody Drugs, by Country, 2023
Figure 30: Chinese Market for Antibody Drugs, 2021-2029
Figure 31: Japanese Market for Antibody Drugs, 2021-2029
Figure 32: Indian Market for Antibody Drugs, 2021-2029
Figure 33: Australian Market for Antibody Drugs, 2021-2029
Figure 34: South Korean Market for Antibody Drugs, 2021-2029
Figure 35: Rest of Asia-Pacific Market for Antibody Drugs, 2021-2029
Figure 36: Global Market Share of Human Monoclonal Antibodies, by Key Manufacturers/Suppliers, 2023
Figure 37: Global Market Share of Humanized Monoclonal Antibodies, by Key Manufacturers/Suppliers, 2023
Figure 38: Global Market Share of Chimeric Monoclonal Antibodies, by Key Manufacturers/Suppliers, 2023
Figure 39: Key ESG Metrics of Antibody Drugs Companies
Figure 40: AbbVie Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 41: AbbVie Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 42: Amgen Inc.: Revenue Shares, by Product, FY 2023
Figure 43: Amgen Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 44: AstraZeneca: Revenue Shares, by Therapy Areas, FY 2023
Figure 45: AstraZeneca: Revenue Shares, by Region/Country, FY 2023
Figure 46: Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
Figure 47: Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
Figure 48: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 49: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 50: Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 51: Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 52: Lilly: Revenue Shares, by Business Unit, FY 2023
Figure 53: Lilly: Revenue Shares, by Country/Region, FY 2023
Figure 54: Merck KGaA: Revenue Shares, by Business Unit, FY 2023
Figure 55: Merck KGaA: Revenue Shares, by Country/Region, FY 2023
Figure 56: Novartis AG: Revenue Shares, by Business Unit, FY 2023
Figure 57: Novartis AG: Revenue Shares, by Country/Region, FY 2023
Figure 58: Pfizer Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 59: Pfizer Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 60: Regeneron Pharmaceuticals Inc.: Revenue Shares, by Product Sales, FY 2023
Figure 61: Regeneron Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 62: Sanofi: Revenue Shares, by Business Unit, FY 2023
Figure 63: Sanofi: Revenue Shares, by Country/ Region, FY 2023
